Laboratorio Reig Jofre : 2018 08 27 - Transactions within the shares buyback program (PDF)
August 27, 2018 at 08:02 am EDT
Share
CNMV Edison, 4 28006 Madrid
Barcelona (Spain), August 27, 2018
RELEVANT FACT
In accordance with the Article 228 of Royal Legislative Decree 4/2015, dated 23 October, which enacts the consolidated text of the Securities Market Act, and in relation to the Shares Buyback Temporary Program reported on Relevant Fact of June 25, 2018 with registration number 268269, LABORATORIO REIG JOFRE SA ("Reig Jofre" or "the Company"), informs that there have been no purchases in the week of August 20, 2018.
Adolf Rousaud
Secretary of the Board of Directors
Attachments
Original document
Permalink
Disclaimer
Laboratorio Reig Jofre SA published this content on 27 August 2018 and is solely responsible for the information contained herein. Distributed by Public, unedited and unaltered, on 27 August 2018 12:01:03 UTC
Laboratorio Reig Jofre SA, formerly Natraceutical SA, is a Spain-based company primarily engaged in the research, development, manufacturing and marketing of drugs. The Companyâs activities are divided into four business divisions: Industrial Services, providing production services for third parties; Pharma, selling own pharmaceuticals under a range of brands, such as Reig Jofre, Medea, Orravan, Bioglan and Sala; Reaserch and Development (R&D) and Regulatory, including the development of indications for existing molecules, as well as generics and molecular diagnostics, among others; and Biotech, offering biopharmaceutical support services, such as analytical and process development, quality control and assurance, as well as stability studies. The Company also provides nutritional cosmetics, and food supplements, among others. It operates worldwide in Europe, Africa, the Americas, Australia and Asia through a number of subsidiaries, including Chiesi Espana SA and Oryzon Genomics SA.
LABORATORIO REIG JOFRE, S.A. 
